1. Evogene's CEO will present at H.C. Wainwright Conference on September 10. 2. Focus on maximizing ChemPass AI's potential in pharmaceuticals and agriculture. 3. One-on-one meetings available for investors at the conference.
A presentation at a significant investment conference can elevate investor interest, as evidenced by past events where CEOs showcasing innovations led to price boosts for companies. Evogene's highlight of its proprietary technology could attract partnerships and investor attention.
The focus on ChemPass AI positions Evogene prominently in sectors with high growth potential, impacting overall investor sentiment and suggesting potential future revenue streams.
Immediate investor interest may arise from the conference, similar to previous instances where companies experienced short-term stock price increases following industry events. The heightened visibility around EVGN could enhance its market perception quickly.
REHOVOT, Israel, Aug. 28, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology and chemistry company, today announced that Ofer Haviv, Evogene's President and CEO, will present at the H.C. Wainwright 27th Annual Global Investment Conference, 2025, taking place in New York, from September 8-10, 2025.
Mr. Haviv's in-person presentation will highlight Evogene's new strategic focus on maximizing the value of ChemPass AI, the company's proprietary generative AI tech-engine, for the discovery and optimization of small molecules in both the pharmaceutical and agriculture industries. The presentation is scheduled for Wednesday, September 10, 2025, at 1:00 PM ET.
Mr. Haviv will also be available for one-on-one meetings. Interested investors and companies attending the conference are welcome to contact Evogene's Investor Relations team (details below) or, for H.C. Wainwright clients, schedule meetings directly through the conference's online platform.
About Evogene Ltd.
Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) is a pioneering AI-driven discovery and development company focused on creating novel small molecules for the pharmaceutical and ag-chemical industries. At the heart of Evogene's innovation is ChemPass AI, a proprietary generative AI tech-engine purpose-built to design highly potent and unique small molecules optimized across multiple critical parameters. By leveraging its tech-engine, Evogene address key challenges in small molecule discovery and optimization – significantly increasing the probability of success while reducing time and development costs. Evogene's powerful tech-engine drives product innovation through both strategic partnerships and collaborations, as well as through its internal proprietary product pipelines.
For more information, please visit: www.evogene.com.
Contact:
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-to-present-at-hc-wainwright-27th-annual-global-investment-conference-in-new-york-302540962.html
SOURCE Evogene